In a phase I/II trial, the combinations of quizartinib with azacitidine or LDAC were evaluated in ND or RR FLT3-ITD MDS-AML patients, producing a median OS of 19.2 months (quizartinib/azacitidine) and 8.5 months (quizartinib/LDAC) in the frontline setting and 10.5 months (quizartinib/azacitidine) and 6.4 months (quizartinib/LDAC) in the R/R setting [182]. The gene discussed is FLT3; the disease is acute myeloid leukemia.